COVID-19 Antibody Treatment Study
COVID-19 Antibody Treatment Trials in Columbus
Aventiv Research is currently participating in an investigational COVID-19 monoclonal antibody (mAb) treatment study at our Columbus, Ohio location. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the pandemic spread of coronavirus disease 2019 (COVID-19), which in critical cases results in pulmonary failure, respiratory complications, and death. There is an urgent need for effective therapeutics to modify disease outcomes. You can join the fight against COVID-19 by volunteering.
COVID-19 Monoclonal Antibody (mAb) Treatment Study
The primary objective of this clinical trial is to characterize the effect of an investigational drug, compared to placebo, on SARS-CoV-2 viral load and viral clearance. You may qualify for this study if you are an adult who is currently not hospitalized and have one or more mild or moderate COVID-19 symptoms such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion.
We are specifically looking for adults who have at least one of the following high-risk factors:
- Are at least 65 years of age
- Have a BMI (body mass index) of at least 35
- Are at least 55 years of age and have a BMI of at least 30, and have history of stroke or certain heart issues
As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.
Ready to Volunteer?
Volunteer today to see if you qualify for our COVID-19 monoclonal antibody (mAb) treatment study. *Qualified volunteers may be compensated for time and travel.